Effectiveness of a Culturally Tailored HIV and Sexually Transmitted Infection Prevention Intervention for Black Women in Community Supervision Programs: A Randomized Clinical Trial.
Adult
Black or African American
Chlamydia Infections
/ prevention & control
Community Health Services
/ organization & administration
Culturally Competent Care
Female
Gonorrhea
/ prevention & control
HIV Infections
/ diagnosis
Humans
New York City
Prisoners
/ education
Trichomonas Vaginitis
/ prevention & control
Unsafe Sex
/ statistics & numerical data
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Concentrated epidemics of HIV and sexually transmitted infections (STIs) have persisted among Black women in community supervision programs (CSPs) in the United States. Accumulating research has highlighted the effectiveness of culturally tailored HIV/STI interventions for Black women; however, there is a dearth of such interventions for the large number of Black women in CSPs. To determine the effectiveness of a 5-session culturally tailored group-based intervention (Empowering African-American Women on the Road to Health [E-WORTH]) with individualized computerized modules and streamlined HIV testing in reducing STIs and condomless sex vs a 1-session streamlined HIV testing control condition. This randomized clinical trial was conducted from November 18, 2015, (first recruitment) to August 20, 2019 (last 12-month follow-up). Black women mandated to probation, parole, or alternative-to-incarceration programs in New York City who had a history of drug use were recruited and randomized to receive either E-WORTH or a streamlined HIV testing control condition. Both conditions were delivered by Black female staff at a large CSP. The analysis took an intention-to-treat approach. E-WORTH included a 1-hour individual HIV testing and orientation session and 4 weekly 90-minute group sessions. The control condition included one 30-minute session of HIV testing and information. Primary outcomes were incidence of any STI (biologically assayed chlamydia, gonorrhea, and Trichomonas vaginalis) at the 12-month assessment and the number of condomless acts of vaginal or anal intercourse in the past 90 days during the 12-month period. A total of 352 participants who identified as Black or African American were enrolled, including 79 (22.5%) who also identified as Latinx. The mean (SD) age was 32.4 (11.0) years. A total of 172 participants (48.9%) were assigned to the E-WORTH condition, and 180 (51.1%) were assigned to the control condition. Compared with control participants, participants assigned to the E-WORTH condition had 54% lower odds of testing positive for any STI at the 12-month follow-up (odds ratio, 0.46; 95% CI, 0.25-0.88; P = .01) and reported 38% fewer acts of condomless vaginal or anal intercourse during the 12-month period (incidence rate ratio, 0.62; 95% CI, 0.39-0.97; P = .04). The magnitudes of effects found across biological and behavioral outcomes in this randomized clinical trial indicate the feasibility and effectiveness of implementing E-WORTH in real-world CSPs. The findings lend further evidence to the promise of culturally tailored HIV/STI interventions for Black women. ClinicalTrials.gov Identifier: NCT02391233.
Identifiants
pubmed: 33835175
pii: 2778343
doi: 10.1001/jamanetworkopen.2021.5226
pmc: PMC8035652
doi:
Banques de données
ClinicalTrials.gov
['NCT02391233']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e215226Subventions
Organisme : NIDA NIH HHS
ID : R01 DA038122
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Am J Public Health. 2007 Jun;97(6):1034-40
pubmed: 17463391
Am J Public Health. 2013 Dec;103(12):2226-33
pubmed: 24134367
Sex Transm Infect. 2019 Feb;95(1):36-42
pubmed: 30341233
Am J Public Health. 2012 Jun;102(6):1160-7
pubmed: 22515871
Int J STD AIDS. 2017 Feb;28(2):160-169
pubmed: 26887890
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):581-9
pubmed: 18645513
J Psychoactive Drugs. 2003 Oct-Dec;35(4):435-43
pubmed: 14986872
Soc Work. 2000 Jan;45(1):9-25
pubmed: 10634083
J Public Health Manag Pract. 2020 May/Jun;26(3):201-205
pubmed: 32235203
Trials. 2018 Sep 10;19(1):486
pubmed: 30201039
Milbank Q. 2016 Mar;94(1):126-62
pubmed: 26994712
Am J Public Health. 2017 Dec;107(12):e13-e21
pubmed: 29048965
PLoS One. 2014 Nov 05;9(11):e111528
pubmed: 25372149
Sex Transm Dis. 2016 Oct;43(10):617-22
pubmed: 27631355
AIDS Behav. 2017 Dec;21(12):3527-3548
pubmed: 28534199
Sex Transm Dis. 2007 Jun;34(6):319-32
pubmed: 17038965
AIDS Behav. 2007 Jan;11(1):25-47
pubmed: 16917668
Lancet. 2017 Apr 8;389(10077):1453-1463
pubmed: 28402827
Am J Public Health. 2016 Jul;106(7):1278-86
pubmed: 27077342
Drug Alcohol Depend. 2013 Feb 1;128(1-2):90-7
pubmed: 22971593
J Acquir Immune Defic Syndr. 2013 Jun 1;63 Suppl 1:S36-43
pubmed: 23673884
AIDS Educ Prev. 2004 Aug;16(4):367-85
pubmed: 15342338
Subst Abuse Treat Prev Policy. 2019 Jan 3;14(1):1
pubmed: 30606266
Int J STD AIDS. 2011 Apr;22(4):218-24
pubmed: 21515755
Transl Behav Med. 2017 Dec;7(4):821-831
pubmed: 28397157
Arch Intern Med. 2010 Sep 27;170(17):1594-601
pubmed: 20625011